| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Entero Therapeutics, Inc. (NASDAQ: ENTO), formerly known as First Wave BioPharma, is a clinical-stage biopharmaceutical company focused on developing targeted and non-systemic therapies for gastrointestinal (GI) diseases. The company’s pipeline includes latiglutenase for celiac disease, adrulipase for fat digestion disorders, capeserod for gastroparesis, and niclosamide for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Additionally, Entero is advancing CypCel, a digital health tool for celiac disease management. Headquartered in Boca Raton, Florida, Entero Therapeutics operates in the high-growth biotechnology sector, addressing unmet medical needs in GI disorders—a market projected to expand significantly due to rising prevalence and demand for innovative treatments. The company’s diversified approach combines biologics, small molecules, and digital health solutions, positioning it as a unique player in the GI therapeutics space.
Entero Therapeutics presents a high-risk, high-reward investment opportunity due to its clinical-stage pipeline targeting significant unmet needs in gastrointestinal diseases. The company’s lead candidates, particularly niclosamide for IBD and latiglutenase for celiac disease, could capture substantial market share if approved. However, with no current revenue, negative earnings, and limited cash reserves ($163K as of latest reporting), Entero faces liquidity risks and potential dilution from future financing. The low market cap (~$1.8M) and beta (0.81) suggest volatility but also potential upside if clinical milestones are met. Investors should closely monitor trial progress, partnerships, and funding developments.
Entero Therapeutics competes in the crowded GI therapeutics market, where differentiation hinges on clinical efficacy, safety, and patient convenience. Its primary competitive advantage lies in its diversified pipeline, which spans biologics (latiglutenase, adrulipase), small molecules (niclosamide, capeserod), and digital health (CypCel). Niclosamide, a repurposed anti-inflammatory drug, could stand out in IBD due to its oral delivery and non-systemic mechanism—a contrast to injectable biologics like Humira or Stelara. However, Entero lacks commercial infrastructure and faces competition from well-capitalized peers with approved GI drugs (e.g., Takeda’s Entyvio, AbbVie’s Skyrizi). The company’s micro-cap status and limited cash runway further constrain its ability to independently advance multiple candidates. Success will depend on strategic partnerships, accelerated regulatory pathways (e.g., orphan drug designations), and demonstrating superior patient outcomes in mid-to-late-stage trials.